New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group

the European EGPA Study Group

Research output: Contribution to journalArticlepeer-review

Abstract

The European Eosinophilic Granulomatosis with Polyangiitis (EGPA) study group first gathered in Firenze in December 2018. The discussion was centred around the clinical and therapeutic needs in EGPA which still remain unmet. Indeed, EGPA is a puzzling and rare disease which shares clinical features with other anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAVs) and hypereosinophilic syndromes (HESs). Some of the recommendations published in 2015 are based on data derived from EGPA-related diseases, rather than from EGPA itself, and therefore need to be updated. Thus, the aim of the meeting was to stimulate ongoing research, to promote collaborative European studies and to define the main issues on which future studies should be focused. Current fields of research on EGPA include potential serological biomarkers of disease activity and of specific organ involvement, possible links between different genetic variants and clinical phenotypes, and new therapeutic perspectives. Herein, we give an overview of the meeting with the goal to stimulate an international collaboration and new points of discussion.

Original languageEnglish
JournalInternal and Emergency Medicine
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • ANCA
  • Eosinophilic granulomatosis with polyangiitis
  • Eosinophils
  • Mepolizumab
  • Rituximab
  • Vasculitis

ASJC Scopus subject areas

  • Internal Medicine
  • Emergency Medicine

Fingerprint Dive into the research topics of 'New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group'. Together they form a unique fingerprint.

Cite this